Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/CJC-1295> ?p ?o }
Showing triples 1 to 76 of
76
with 100 triples per page.
- CJC-1295 abstract "CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies. It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regards to half-life.CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans. With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 1.5- to 3-fold for 9 to 11 days. The drug has an estimated half-life of about 6 to 8 days in humans. With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion. It increases the half-life of acting agents by bioconjugation.CJC-1295 was under investigation for the treatment of lipodystrophy and growth hormone deficiency and reached phase II clinical trials but was discontinued upon the death of one of the trial subjects. The attending physician of the trial believed that the most likely explanation for the incident was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion, and that the occurrence was unrelated to treatment with CJC-1295. In any case, research was terminated nonetheless as a precaution. CJC-1295 has found black market use for bodybuilding purposes, with this, in some countries such as the Netherlands, being an illicit use.".
- CJC-1295 atcPrefix "None".
- CJC-1295 casNumber "863288-34-0".
- CJC-1295 pubchem "56841945".
- CJC-1295 wikiPageExternalLink 800018006.
- CJC-1295 wikiPageID "18609845".
- CJC-1295 wikiPageLength "10724".
- CJC-1295 wikiPageOutDegree "32".
- CJC-1295 wikiPageRevisionID "705929773".
- CJC-1295 wikiPageWikiLink Bioconjugation.
- CJC-1295 wikiPageWikiLink Black_market.
- CJC-1295 wikiPageWikiLink Blood_plasma.
- CJC-1295 wikiPageWikiLink Bodybuilding.
- CJC-1295 wikiPageWikiLink Category:Growth_hormone-releasing_hormone_receptor_agonists.
- CJC-1295 wikiPageWikiLink Category:Growth_hormone_secretagogues.
- CJC-1295 wikiPageWikiLink Category:Hormonal_agents.
- CJC-1295 wikiPageWikiLink Category:Peptides.
- CJC-1295 wikiPageWikiLink Clinical_trial.
- CJC-1295 wikiPageWikiLink ConjuChem.
- CJC-1295 wikiPageWikiLink Coronary_artery_disease.
- CJC-1295 wikiPageWikiLink Growth_hormone.
- CJC-1295 wikiPageWikiLink Growth_hormone_deficiency.
- CJC-1295 wikiPageWikiLink Growth_hormone_secretagogue.
- CJC-1295 wikiPageWikiLink Growth_hormone–releasing_hormone.
- CJC-1295 wikiPageWikiLink Half-life.
- CJC-1295 wikiPageWikiLink Insulin-like_growth_factor_1.
- CJC-1295 wikiPageWikiLink Lipodystrophy.
- CJC-1295 wikiPageWikiLink Modified_GRF_(1-29).
- CJC-1295 wikiPageWikiLink Netherlands.
- CJC-1295 wikiPageWikiLink Organic_compound.
- CJC-1295 wikiPageWikiLink Pharmacokinetics.
- CJC-1295 wikiPageWikiLink Phases_of_clinical_research.
- CJC-1295 wikiPageWikiLink Prohibition_of_drugs.
- CJC-1295 wikiPageWikiLink Sermorelin.
- CJC-1295 wikiPageWikiLink Structural_analog.
- CJC-1295 wikiPageWikiLink Subcutaneous_injection.
- CJC-1295 wikiPageWikiLink Tesamorelin.
- CJC-1295 wikiPageWikiLinkText "CJC-1295".
- CJC-1295 atcPrefix "None".
- CJC-1295 c "152".
- CJC-1295 casNumber "863288".
- CJC-1295 h "252".
- CJC-1295 inchi "InChI=1S/C152H252N44O42/c1-22-79118147189-106141196-120149180-99132190-111145185-105140178-96128177-94133193-117146187-100134170-82123175-97130183-103138191-109143172-83122174-95127176-93129182-102137184-101136179-98131186-108142195-119148188-104139192-110144173-9238-31-57-166-150161/h24-26,34-35,41-48,73-85,91-111,117-120,197-202H,22-23,27-33,36-40,49-72,153-155H2,1-21H3,/t79-,80-,81+,82-,83-,84-,85+,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,117-,118-,119-,120-/m0/s1".
- CJC-1295 inchikey "XOZMWINMZMMOBR-HRDSVTNWSA-N".
- CJC-1295 molecularWeight "3367.89688".
- CJC-1295 n "44".
- CJC-1295 o "42".
- CJC-1295 pubchem "56841945".
- CJC-1295 routesOfAdministration Subcutaneous_injection.
- CJC-1295 smiles "CCCCNCCNCCNCCNCCN".
- CJC-1295 wikiPageUsesTemplate Template:Drugbox.
- CJC-1295 wikiPageUsesTemplate Template:Peptidergics.
- CJC-1295 wikiPageUsesTemplate Template:Reflist.
- CJC-1295 wikiPageUsesTemplate Template:Systemic-hormonal-drug-stub.
- CJC-1295 subject Category:Growth_hormone-releasing_hormone_receptor_agonists.
- CJC-1295 subject Category:Growth_hormone_secretagogues.
- CJC-1295 subject Category:Hormonal_agents.
- CJC-1295 subject Category:Peptides.
- CJC-1295 hypernym Analogue.
- CJC-1295 type ChemicalSubstance.
- CJC-1295 type Drug.
- CJC-1295 type Hormone.
- CJC-1295 type Peptide.
- CJC-1295 type Preparation.
- CJC-1295 type Redirect.
- CJC-1295 type ChemicalObject.
- CJC-1295 type Thing.
- CJC-1295 type Q8386.
- CJC-1295 comment "CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies.".
- CJC-1295 label "CJC-1295".
- CJC-1295 sameAs Q5012018.
- CJC-1295 sameAs m.013dbz3w.
- CJC-1295 sameAs m.03kv5s.
- CJC-1295 sameAs Q5012018.
- CJC-1295 wasDerivedFrom CJC-1295?oldid=705929773.
- CJC-1295 isPrimaryTopicOf CJC-1295.